Bereum’s postbiotic research explores how concentrated inactive cells can influence gut health, even at extremely low doses.
In a randomized human trial using 4 mg and 10 mg per arm, EF-2001® and beLP1® showed measurable effects on GI comfort, microbiome balance, and stress indicators.
The findings reflect Bereum’s decades-long work in postbiotic science and its pursuit of practical, dose-efficient solutions for diverse applications.
